China Pharma Holdings, Inc. filed a preliminary proxy statement on October 30, 2026, soliciting stockholder votes for its Annual Meeting of Stockholders scheduled for December 22, 2026, covering the fiscal year ended December 31, 2025.

Key Highlights

  • Annual Meeting date: December 22, 2026, at 9:00 p.m. local time (8:00 a.m. Eastern Time), at Conference Room, 2nd Floor, Jiahai Building, No. 17 Jinpan Road, Haikou, Hainan Province, China 570216.
  • Reverse stock split proposal: Stockholders will be asked to approve a reverse stock split at a ratio of up to 1:50, under which each holder would receive one share of common stock for every pro rata twenty shares held, based on the ratio applied within the stated range.
  • Director election: Three independent director nominees are proposed for election to the Board of Directors to serve until the next annual meeting.
  • Incentive plan amendment: Stockholders will vote on Amendment No. 4 to the Company's Amended and Restated 2010 Long-Term Incentive Plan.
  • Record date: November 2, 2026 is the record date for stockholders entitled to notice and to vote at the Annual Meeting.
  • Proxy materials distribution: The Notice of Internet Availability of Proxy Materials is intended to be sent to stockholders on November 11, 2026.
  • Common stock par value: The Company's common stock carries a par value of $0.001 per share.

China Pharma Holdings Calls Annual Meeting With Reverse Split and Plan Amendment on Agenda

China Pharma Holdings, Inc., a Nevada corporation headquartered in Haikou, Hainan Province, China, filed a preliminary proxy statement inviting stockholders of record to its Annual Meeting for fiscal year ended December 31, 2025. According to the filing, the meeting will be held on December 22, 2026, and the board is soliciting proxies to ensure representation on all matters before the stockholders. Zhilin Li, Chairman of the Board, signed the accompanying letter to stockholders.

The most prominent proposal before stockholders, according to the filing, is the authorization of a reverse stock split of the Company's outstanding common stock at a ratio of up to 1:50. The filing states that the amendment to the Articles of Incorporation would result in each stockholder receiving one share of common stock for every pro rata twenty shares held, based on the ratio applied within the stated range. The filing also calls for the election of three independent director nominees and a vote on Amendment No. 4 to the Amended and Restated 2010 Long-Term Incentive Plan.

The filing states that only stockholders of record as of the close of business on November 2, 2026 are entitled to vote. A quorum requires the presence, in person or by proxy, of one-third of the outstanding shares of common stock as of the record date. The filing notes that broker non-votes are included for quorum purposes. Stockholders may cast votes via phone, fax, internet, or mail until 11:59 p.m. Eastern Time on December 21, 2026, or in person at the meeting. The filing does not specify the total number of shares outstanding as of the record date, leaving that figure blank in the proxy text.

What Was Disclosed

China Pharma Holdings filed a preliminary proxy statement for its December 22, 2026 annual meeting, covering three proposals: election of three independent directors, approval of a reverse stock split at up to 1:50, and Amendment No. 4 to its 2010 Long-Term Incentive Plan.